Literature DB >> 21145726

Framework models of tumor dormancy from patient-derived observations.

Christoph A Klein1.   

Abstract

Unusually long latency periods between the treatment of primary tumors and metastatic recurrences are commonly thought to prove the existence and relevance of clinical tumor dormancy. However, careful consideration of disease courses and cancer growth rates leads to the conclusion that clinical dormancy may be everything from non-existent to much more frequent than originally thought. On the other hand, cellular dormancy defined as a non-productive state of disseminated tumor cells is very frequent, while homeostatic mechanisms such as angiogenic and immunological control contribute to the chronicity of cancer. This review attempts to provide a conceptual framework for the study of dormancy, which may guide clinical and experimental research.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21145726     DOI: 10.1016/j.gde.2010.10.011

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  89 in total

Review 1.  Deregulation of cell signaling in cancer.

Authors:  Filippo G Giancotti
Journal:  FEBS Lett       Date:  2014-02-20       Impact factor: 4.124

2.  Metabolic shifts in residual breast cancer drive tumor recurrence.

Authors:  Kristina M Havas; Vladislava Milchevskaya; Ksenija Radic; Ashna Alladin; Eleni Kafkia; Marta Garcia; Jens Stolte; Bernd Klaus; Nicole Rotmensz; Toby J Gibson; Barbara Burwinkel; Andreas Schneeweiss; Giancarlo Pruneri; Kiran R Patil; Rocio Sotillo; Martin Jechlinger
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 3.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

4.  Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer.

Authors:  Chen Chen; Zhilu Li; Yuan Yang; Tingxiu Xiang; Weihong Song; Shengchun Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 5.  Mechanisms of disseminated cancer cell dormancy: an awakening field.

Authors:  María Soledad Sosa; Paloma Bragado; Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2014-08-14       Impact factor: 60.716

Review 6.  Metastatic stem cells: sources, niches, and vital pathways.

Authors:  Thordur Oskarsson; Eduard Batlle; Joan Massagué
Journal:  Cell Stem Cell       Date:  2014-03-06       Impact factor: 24.633

Review 7.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

8.  In vivo photoswitchable flow cytometry for direct tracking of single circulating tumor cells.

Authors:  Dmitry A Nedosekin; Vladislav V Verkhusha; Alexander V Melerzanov; Vladimir P Zharov; Ekaterina I Galanzha
Journal:  Chem Biol       Date:  2014-05-08

9.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Authors:  Wen Liu; Carolyn J Vivian; Amanda E Brinker; Kelsey R Hampton; Evi Lianidou; Danny R Welch
Journal:  Cancer Microenviron       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.